Lucía Bailón

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff et al. · The Lancet Infectious Diseases · 2022 · 84 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial

Lucía Bailón, Anuska Llano, Samandhy Cedeño et al. · Nature Medicine · 2022 · 68 citations · Full text

Vaccination, Human Retrovirus, Immunology +8

Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution

Susana Benet, Oscar Blanch-Lombarte, Erola Ainsua‐Enrich et al. · The Journal of Infectious Diseases · 2022 · 36 citations · Full text

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

Júlia Corominas, Carme Garriga, Antoni Prenafeta et al. · The Lancet Regional Health - Europe · 2023 · 31 citations · Full text

Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial

Lucía Bailón, José Moltó, Adrián Curran et al. · Nature Communications · 2025 · 18 citations · Full text